Journal Article

DKFZ-2017-01831

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.

Dick, J. ; Lang, N. ; Slynko, A.DKFZ* ; Kopp-Schneider, A.DKFZ* ; Schulz, C. ; Dimitrakopoulou-Strauss, A.DKFZ* ; Enk, A. H. ; Hassel, J. C.

2016
Future Medicine Ltd London

This record in other databases:  

Please use a persistent id in citations: doi:10.2217/imt-2016-0083

Abstract: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.Changes in LDH level and side effects correlate with response to therapy and survival.

Keyword(s): Antibodies, Monoclonal ; Biomarkers, Pharmacological ; CTLA-4 Antigen ; ipilimumab ; C-Reactive Protein ; L-Lactate Dehydrogenase

---

Contributing Institute(s):

1. Biostatistik (C060)
2. KKE Nuklearmedizin (E060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2016

---

Database coverage:
; BIOSIS Previews ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---